Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
18 evidence topics · 15 sources
Cirrhosis: prevalence in US adults with MASLD, NHANES 2017 to 2020
“We used National Health and Nutrition Examination Surveys (NHANES 2017-2020) to estimate the prevalence of cirrhosis and clinically significant (CS)-portal hypertension in alcohol-associated liver disease (ALD), MetALD, viral hepatitis to include chronic hepatitis B (CHB) and chronic hepatitis C (CHC), and metabolic dysfunction-associated steatotic liver disease (MASLD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the general population, the prevalence of ALD-cirrhosis was 0.08%, MetALD-cirrhosis 0.19%, CHB-cirrhosis 0.01%, CHC-cirrhosis 0.10%, MASLD-cirrhosis 1.27%, ALD + viral hepatitis-cirrhosis 0.08%, and other cirrhosis 0.87%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of cirrhosis in the United States is 2.6% while the prevalence of CS-portal hypertension is 0.98%. Individuals with MASLD comprise the majority of US residents with cirrhosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cirrhosis: progression to clinical decompensation
“Those with cirrhosis require biannual screening for HCC as well as screening for varices and monitoring for signs or symptoms of decompensation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic decompensation and hepatocellular cancer by fibrosis stage: adults with biopsy-confirmed NAFLD, NASH CRN NAFLD Database 2
“A total of 1773 adults with NAFLD were followed for a median of 4 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included adults who had liver biopsies that could be evaluated and that revealed NAFLD and who had at least one follow-up visit after 48 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Projected decompensated cirrhosis and hepatocellular carcinoma: US NAFLD population, 2015 to 2030 model
“Incidence of decompensated cirrhosis will increase 168% to 105,430 cases by 2030, while incidence of HCC will increase by 137% to 12,240 cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Projected changes in NAFLD‐related cirrhosis, advanced liver disease, and liver‐related mortality were quantified through 2030.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatocellular carcinoma: incidence in US veterans with NAFLD
“We compared 296,707 NAFLD patients with 296,707 matched controls. During 2,382,289 person-years [PY] of follow-up, 490 NAFLD patients developed HCC (0.21/1000 PY). HCC incidence was significantly higher among NAFLD patients vs. controls (0.02/1000 PY; hazard ratio, 7.62, 95% confidence interval=5.76–10.09). Among patients with NAFLD, those with cirrhosis had the highest annual incidence of HCC (10.6 /1000 PY).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In medical record reviews, 20% of NAFLD patients with HCC had no evidence of cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We conducted a retrospective cohort study from a total of 130 facilities in the Veterans Health Administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatocellular carcinoma without cirrhosis: systematic review and meta-analysis of NAFLD-related HCC
“Of 3631 records identified, 61 studies (done between January, 1980, and May, 2021; 94 636 patients) met inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A higher proportion of patients with NAFLD-related hepatocellular carcinoma did not have cirrhosis (38·5%, 95% CI 27·9–50·2) compared with patients with hepatocellular carcinoma secondary to other causes (14·6%, 8·7–23·4; p<0·0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatocellular carcinoma risk with F3 fibrosis and surveillance recommendations
Liver transplantation: NASH/MASH share of US and European transplant recipients, 2000 to 2022
“Data from 2 large LT registries: the US Scientific Registry of Transplant Recipients (SRTR) and the European Liver Transplant Registry (ELTR), years 2000-2022, were compared.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NASH/MASH also increased: SRTR 9%-28%, ELTR 5%-12%. From SRTR, NASH/MASH was the common etiology by 2022;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ALD and NASH/MASH are now leading indications for liver transplantation in 2 large global regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liver transplantation: MASH share of the US waitlist for steatotic liver disease, 2010 to 2023
“Steatotic liver disease (SLD) is the leading indication for liver transplantation (LT) among U.S. adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 65,675 adults on the LT waitlist secondary to SLD (median age 57 years old [IQR 50–64], 65.1% men, 74.9% NHW, 3.2% AA, 17.9% Hispanic, 2.5% API, 1.1% AI/AN, and 0.5% multiracial) from 2010 to 2023 (Table 1). Overall, 44.5% had MASH (vs 55.5% ALD) while 17.2% had HCC (vs 82.8% non-HCC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular disease: risk of fatal and non-fatal events by severity of NAFLD, meta-analysis
“We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CVD events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NAFLD was associated with a moderately increased risk of fatal or non-fatal CVD events (pooled random-effects HR 1·45, 95% CI 1·31-1·61;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This risk markedly increased across the severity of NAFLD, especially the stage of fibrosis (pooled random-effects HR 2·50, 95% CI 1·68-3·72;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CVD risk is further increased with more advanced liver disease, especially with higher fibrosis stage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular disease: principal cause of death, American Heart Association scientific statement
Cardiovascular disease: atherosclerosis, heart failure, and arrhythmia
“The most common causes of death in patients with NAFLD overall are cardiovascular disease (CVD) and nonhepatic malignancy, followed by liver disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A strong association exists between NAFLD and atherosclerotic heart disease, heart failure, and arrhythmias, particularly atrial fibrillation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, in a large prospectively studied observational cohort, the incidence of cardiac events was the same across all fibrosis stages; however, the number of cardiac events was relatively low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic kidney disease: risk of incident CKD, meta-analysis
“We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CKD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NAFLD was associated with a moderately increased risk of incident CKD (n=10 studies; random-effects HR 1.43, 95% CI 1.33 to 1.54;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All risks were independent of age, sex, obesity, hypertension, diabetes and other conventional CKD risk factors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chronic kidney disease: higher prevalence with advanced fibrosis
“A meta-analysis of 20 cross-sectional studies (n = 28,000 individuals) found that NAFLD was associated with a 2-fold increased prevalence of CKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recently published data from the NASH CRN demonstrate a higher prevalence of CKD in patients with advanced fibrosis compared with lower fibrosis stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
New-onset nonhepatic outcomes: adults with biopsy-confirmed NAFLD, NASH CRN NAFLD Database 2
“New-onset hypertension (7.8 events per 100 person-years) was the most common new nonhepatic outcome, followed by type 2 diabetes (4.8 events per 100 person-years), chronic kidney disease (2.5 events per 100 person-years), cardiac events (0.8 events per 100 person-years), nonhepatic cancer (0.8 events per 100 person-years), and cerebrovascular events (0.4 events per 100 person-years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Extrahepatic cancer: risk of incident extrahepatic cancers, meta-analysis
“We performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of extrahepatic cancers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NAFLD was significantly associated with a nearly 1.5-fold to twofold increased risk of developing GI cancers (oesophagus, stomach, pancreas or colorectal cancers). Furthermore, NAFLD was associated with an approximately 1.2-fold to 1.5-fold increased risk of developing lung, breast, gynaecological or urinary system cancers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Extrahepatic cancer: leading contributor to excess mortality in biopsy-confirmed NAFLD, Sweden
“This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966–2017; n=10,568).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The excess mortality associated with NAFLD was primarily from extra-hepatic cancer (4.5/1000PY; aHR=2.16, 95%CI=2.03–2.30), followed by cirrhosis (2.7/1000PY; aHR=18.15, 95%CI=14.78–22.30), cardiovascular disease (1.4/1000PY; aHR=1.35, 95%CI=1.26–1.44) and hepatocellular carcinoma (HCC)(1.2/1000PY; aHR=11.12, 95%CI=8.65–14.30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote